Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 20/20 | 0.73 |
| ▸ | CDK2 | P24941 | 20/20 | 0.73 |
| ▸ | CDK1 | P06493 | 15/20 | 0.73 |
| ▸ | CCNB1 | P14635 | 15/20 | 0.73 |
| ▸ | CDK4 | P11802 | 14/20 | 0.73 |
| ▸ | CCND1 | P24385 | 14/20 | 0.73 |
| ▸ | CCND3 | P30281 | 14/20 | 0.73 |
| ▸ | CDK6 | Q00534 | 14/20 | 0.73 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.72 |
| ▸ | CDK7 | P50613 | 9/20 | 0.72 |
| ▸ | CDK9 | P50750 | 9/20 | 0.72 |
| ▸ | CCNH | P51946 | 9/20 | 0.72 |
| ▸ | MNAT1 | P51948 | 9/20 | 0.72 |
| ▸ | CCNK | O75909 | 1/20 | 0.46 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22900961 | 1.00 | CCNE1 (0.73) | CCNE1CDK2CDK1CCNB1CDK4 | |
| SCHEMBL29926999 | 0.99 | CCNE1 (0.74) | CCNE1CDK2CDK1CCNB1CDK4 | |
| SCHEMBL22901218 | 0.99 | CCNE1 (0.74) | CCNE1CDK2CDK1CCNB1CDK4 | |
| SCHEMBL22900924 | 0.98 | CCNE1 (0.74) | CCNE1CDK2CDK1CCNB1CDK4 | |
| SCHEMBL29926275 | 0.98 | CCNE1 (0.74) | CCNE1CDK2CDK1CCNB1CDK4 | |
| SCHEMBL22900834 | 0.97 | CCNE1 (0.75) | CCNE1CDK2CDK1CCNB1CDK4 | |
| SCHEMBL29926579 | 0.97 | CCNE1 (0.75) | CCNE1CDK2CDK1CCNB1CDK4 | |
| SCHEMBL22900818 | 0.96 | CCNE1 (0.75) | CCNE1CDK2CDK1CCNB1CDK4 | |
| SCHEMBL29926416 | 0.96 | CCNE1 (0.75) | CCNE1CDK2CDK1CCNB1CDK4 | |
| SCHEMBL22900920 | 0.95 | CCNE1 (0.78) | CCNE1CDK2CDK1CCNB1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472791-B2 | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors | INCYTE CORPORATION (US) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472791-B2 | Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors | CDK2, CDK2AP2, CDK4 | CCNE1 42/4885CDK2 1/4885CDK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.